Category Archives: Biotechnology

Passive investing in index funds can generate returns that roughly match the overall market. But if you pick the right individual stocks, you could make more than that. For example, the Level Biotechnology Inc. (GTSM:3118) share price is up 16% in the last year, clearly besting the market return of around 9.9% (not including dividends). Thats a solid performance by our standards! Unfortunately the longer term returns are not so good, with the stock falling 2.1% in the last three years.

Check out our latest analysis for Level Biotechnology

To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term its a weighing machine. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.

During the last year Level Biotechnology grew its earnings per share (EPS) by 16%. The similarity between the EPS growth and the 16% share price gain really stands out. That suggests that the market sentiment around the company hasnt changed much over that time. It makes intuitive sense that the share price and EPS would grow at similar rates.

You can see below how EPS has changed over time (discover the exact values by clicking on the image).

Before buying or selling a stock, we always recommend a close examination of historic growth trends, available here.

As well as measuring the share price return, investors should also consider the total shareholder return (TSR). The TSR incorporates the value of any spin-offs or discounted capital raisings, along with any dividends, based on the assumption that the dividends are reinvested. So for companies that pay a generous dividend, the TSR is often a lot higher than the share price return. As it happens, Level Biotechnologys TSR for the last year was 20%, which exceeds the share price return mentioned earlier. The dividends paid by the company have thusly boosted the total shareholder return.

Its good to see that Level Biotechnology has rewarded shareholders with a total shareholder return of 20% in the last twelve months. And that does include the dividend. Since the one-year TSR is better than the five-year TSR (the latter coming in at 5.3% per year), it would seem that the stocks performance has improved in recent times. Given the share price momentum remains strong, it might be worth taking a closer look at the stock, lest you miss an opportunity. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. For instance, weve identified 4 warning signs for Level Biotechnology (1 cant be ignored) that you should be aware of.

We will like Level Biotechnology better if we see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on TW exchanges.

Love or hate this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Thank you for reading.

Read this article:
Should Level Biotechnology (GTSM:3118) Be Disappointed With Their 16% Profit? - Simply Wall St

A new market report by Verified Market Research on the Nanoparticles in Biotechnology and Pharmaceuticals Market has been released with reliable information and accurate forecasts for a better understanding of the current and future market scenarios. The report offers an in-depth analysis of the global market, including qualitative and quantitative insights, historical data, and estimated projections about the market size and share in the forecast period. The forecasts mentioned in the report have been acquired by using proven research assumptions and methodologies. Hence, this research study serves as an important depository of the information for every market landscape. The report is segmented on the basis of types, end-users, applications, and regional markets.

The research study includes the latest updates about the COVID-19 impact on the Nanoparticles in Biotechnology and Pharmaceuticals sector. The outbreak has broadly influenced the global economic landscape. The report contains a complete breakdown of the current situation in the ever-evolving business sector and estimates the aftereffects of the outbreak on the overall economy.

Get Sample Copy with TOC of the Report to understand the structure of the complete report @ https://www.verifiedmarketresearch.com/download-sample/?rid=19246&utm_source=COD&utm_medium=007

The report also emphasizes the initiatives undertaken by the companies operating in the market including product innovation, product launches, and technological development to help their organization offer more effective products in the market. It also studies notable business events, including corporate deals, mergers and acquisitions, joint ventures, partnerships, product launches, and brand promotions.

Leading Nanoparticles in Biotechnology and Pharmaceuticals manufacturers/companies operating at both regional and global levels:

The report also inspects the financial standing of the leading companies, which includes gross profit, revenue generation, sales volume, sales revenue, manufacturing cost, individual growth rate, and other financial ratios.

The report also focuses on the global industry trends, development patterns of industries, governing factors, growth rate, and competitive analysis of the market, growth opportunities, challenges, investment strategies, and forecasts till 2026. The Nanoparticles in Biotechnology and Pharmaceuticals Market was estimated at USD XX Million/Billion in 2016 and is estimated to reach USD XX Million/Billion by 2026, expanding at a rate of XX% over the forecast period. To calculate the market size, the report provides a thorough analysis of the market by accumulating, studying, and synthesizing primary and secondary data from multiple sources.

To get Incredible Discounts on this Premium Report, Click Here @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=19246&utm_source=COD&utm_medium=007

The market is predicted to witness significant growth over the forecast period, owing to the growing consumer awareness about the benefits of Nanoparticles in Biotechnology and Pharmaceuticals. The increase in disposable income across the key geographies has also impacted the market positively. Moreover, factors like urbanization, high population growth, and a growing middle-class population with higher disposable income are also forecasted to drive market growth.

According to the research report, one of the key challenges that might hinder the market growth is the presence of counter fit products. The market is witnessing the entry of a surging number of alternative products that use inferior ingredients.

Key factors influencing market growth:

Reasons for purchasing this Report from Verified Market Research

Customized Research Report Using Corporate Email Id @ https://www.verifiedmarketresearch.com/product/Nanoparticles-in-Biotechnology-and-Pharmaceuticals-Market/?utm_source=COD&utm_medium=007

Customization of the Report:

Verified Market Research also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

Thank you for reading this article. You can also get chapter-wise sections or region-wise report coverage for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

To summarize, the Nanoparticles in Biotechnology and Pharmaceuticals market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyse data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll Free: +1 (800)-7821768

Email: [emailprotected]

See the article here:
Nanoparticles in Biotechnology and Pharmaceuticals Market 2019 Break Down by Top Companies, Countries, Applications, Challenges, Trends, Opportunities...

NewLeaf Brands Inc (OTCMKTS:NLBIF) informed the shareholders about its recent developments. We Are Kured, which belongs to NewLeaf, introduced innovative CBD flower pre-rolled joints on April 9. The company received an overwhelming response from the customers. To meet the growing demand from customers, the company expects to improve the distribution network in the US.

NewLeaf entered a share swap pact on April 23, 2020, with Levee Street Holdings, LLC, to acquire a stake of 50% for CAD 450,000. Levee Street is established to venture into an alternative beverage like CBD products. Greg Kassanoff founded companies such as Levee Street, and Pioneer Wine and Spirits. He is also working as CEO at MPWS (Mexcor Pioneer Wine and Spirits), which maintains several restaurants and retail relationships across Texas.

The network developed by Greg is playing a vital role in introducing a product line of NewLeaf across the state of Texas. CEO of NewLeaf, Joshua Bartch, said its team is working hard to become a leading player in product categories like hemp, mushroom, and cannabis.

NewLeaf entered pact on April 29, 2020, to take over a vertically integrated firm Mydecine Group, which uses wellness, health, and medicinal properties of compounds available in mushrooms.

NewLeaf signed an accord on May 5, 2020, to clinch a 37.5% stake in Trellis Holdings Oregon, LLC. As per the terms of share exchange the deal, NewLeaf will acquire all of the issued and outstanding capital of Trellis from Benjamin Martch and David Joshua Bartch.

Trellis, which owns several licenses with OLCC in the Oregon state, conducts business operations in recreational and medical cannabis. The company also maintains recreational cannabis cultivation on eleven-acre land in Southern Oregon. In Portland, Oregon, Trellis operates recreational and medical cannabis dispensaries. The company seeks additional licenses to improve canopy cultivation outdoor on 40,000 Sq. Ft.

NewLeaf inducted Robert Roscow as CSO and Damon Michaels as COO on May 12, and 11 2020. The company entered a share exchange deal on May 21, 2020, to acquire MindLeap Health Inc., an advanced telemedicine platform.

Read more from the original source:
BetterLife Pharma Inc. (OTCMKTS:PVOTF) Announce Proposed Merger With Altum Biotechnology and Release Exploratory Study Results - FactsAboutCBD

1.5 Present and future trends in biotechnology

During the twentieth century humankind has harnessed microorganisms to produce useful biochemical including antibiotics, vitamins, amino acids, flavors and colors, as well as specific proteins (Carlier 2001). Some of these proteins have important medical uses such as insulin, human growth hormone and blood factors like erythropoietin. In fact, manufacturers have developed a series of proven, safe, microbial hosts for use in the production of several enzymes (Warke and Chandratre 2003). Further, enzymes that have not been readily available in adequate quantity can be produced using technology. This in turn has opened up important applications beneficial to humankind. Additionally, modern techniques are leading to the development of tailored enzymes with optimized functional properties specific for their intended use. An example of this is the modification in specific proteases so that they work more efficiently in the alkaline environment of detergent formulations. As a result, less of the modified protease is needed to deliver equivalent cleaning power, while using fewer resources during the manufacturing process.

The microbial cell, a bacterium, yeast, or mold, is the key instrument in many enzyme production processes. To optimize the microbial strains for production of the desired enzyme, the strains genetic properties are often modified either through natural evolution or through classical breeding and selection techniques; these classical techniques have been used for decades to improve microbial production strains. The precise methods of genetic modification have been developed. The methods, sometimes termed genetic engineering, are based on processes occurring in nature - the transfer of genes between different cells.

Scientists to transfer genetic material between cells from the same or different species, microorganisms such as yeasts, molds and bacteria with new or improved properties for industrial applications can be developed. In nature, genetic modification has been occurring since life began. Such genetic changes are generally random, with a natural selection process favoring the changes best adapted for survival. Using this process, animal, plant and microbial breeders have likewise selected individuals within a species with desired characteristics for further propagation.

Using the tools of modern biotechnology, modifications can now be made more precisely and with much less chance of developing unwanted secondary changes that could potentially have undesired effects. In nature and in our production systems, microbes do not express only single enzymes. Rather, each microbial cell has the genetic nature to produce many different enzymes. Frequently, only one of these enzyme activities is needed for a specific application and the side activities are removed or substantially reduced during the recovery process. Often, these side activities are unwanted and may even be detrimental to the final use. Additionally, scientists are now able to discover and/or evolve enzymes that will catalyze pure compounds for applications including textile wet processing such as enzymatic desizing with alpha amylase, bioscouring with pectinase, protease, lipase and cellulase enzymes, binary and mixed enzymatic system, and biopolishing with cellulase enzymes, lipase enzyme for improving hydrophilic nature of polyester fibre both greatly reducing unwanted byproduct production as well as making the target product potentially safer and more effective (Buschie-Diller et al 1994).

Modern biotechnology is one tool that can help meet the challenge this growth poses and also contributed to (a) ecofriendly environment (b) safety and health, (c) reduced water demand in manufacturing processes, (e) reduced industrial waste and (f) aided in pollution remediation. Enzymes produced using modern biotechnology contributes to this effort by assuring the availability of safe, pure enzymes that replace harsh chemical processes (reducing energy consumption and environmental burden). Modern tools of biotechnology, enzymes from nature can be accessed which are sufficiently robust to be useful at extremes of pH and temperature and thus hold great promise for replacing certain chemical processes with much cleaner protein-catalyzed processes (Gubitz and Cavaco-Paulo 2001). Just as exciting, these new enzymes can make the dream of converting waste biomass to useful energy an economic reality. Overall, the use of modern biotechnology for enzyme production can have a major impact on improving the cost and quality of products at the same time working towards sustainability.

Enzymes have applications in many fields, including organic synthesis, clinical analysis, textile processes, and finishing, pharmaceuticals, detergents, food production and fermentation. The application of enzymes to organic synthesis is currently attracting more and more attention. The discovery of new microbial enzymes through extensive and persistent screening will open new, simple routes for synthetic processes and consequently, new ways to solve environmental problems (Calafell et al 2005).

Research on enzyme systems for textile processing and finishing has mainly focused on amylases and cellulases. However, recent biotechnology and genetic engineering advances have opened opportunities for successful applications of other enzyme systems, such as lipases, xylanases, laccases, proteases and pectinases (Emilla Csiszar et al 1998). Today, enzymes can be customized for specific target areas; for example, enzymatic degumming of silk, bioscouring of cotton textiles and antifelting and softening of wool. The basic mechanisms involving enzyme systems and interactions with textile substrates are likely noticed. Using several enzyme systems and application conditions, few researchers are being involved in studying the fibre/enzyme interactions and the compatibility of enzymes in combination (Gisela Buschle-Diller, and S. Haig Zeronian 1998).

Biotechnology offers an increasing potential for the production of goods to meet various human needs. In enzyme technology, a subfield of biotechnology, new processes have been and are being developed to manufacture both bulk and high value added products utilizing enzymes as biocatalysts (Tzanko et al 2002). Enzymes are also used to provide services, as in washing and environmental processes, or for analytical and diagnostic purposes. The driving force in the development of enzyme technology, both in academia and industry, has been and will continue to be:

The development of new and better products, processes and services to meet these needs; and/or

The improvement of processes to produce existing products from new raw materials as biomass.

Enzymes from nature can be accessed which are sufficiently robust to be useful at extremes of pH and temperature and thus hold great promise for replacing certain chemical processes with much cleaner protein-catalyzed processes (Csiszar et al 2001). These new enzymes can make the dream of converting waste biomass to useful energy an economic reality. Overall, the use of modern biotechnology for enzyme production can have a major impact on improving the cost and quality of products at the same time working towards sustainability.

Continue reading here:
Biotechnology - an overview | ScienceDirect Topics

An RIT alumnus is helping to lead Bolivias response to the COVID-19 pandemic.

Mohammed Mostajo-Radji 11 (biotechnology) was appointed as Bolivias first ambassador for science, technology and innovation in February. He is typically based out of Silicon Valley, helping to encourage technology investment in Bolivia and facilitating exchanges between universities, technology companies, startups, and more.

But on March 19 he flew back home at the request of Bolivias interim president, Jeanine ez, to help coordinate his countrys efforts to combat COVID-19s spread. His country faces many challenges in fighting the virus, including one of the worlds worst healthcare systems and a unique geographic predicament.

Our countrys high altitude is by far our biggest challenge right now because most of the ventilators dont work appropriately at this level, said Mostajo-Radji. We have large populations living at altitudes above 13,000 feet and most ventilators are made and tested at sea level. In the current market its already extremely difficult to get a ventilator, but maybe only 30 percent of them actually work here.

But he is uniquely equipped to handle the rigors of the job. While at RIT, Mostajo-Radji developed an interest in science diplomacy, minoring in science, technology and society. For his senior thesis, he conducted experiments using Real-time polymerase chain reaction, the same equipment that is now commonly used to test for COVID-19. As he travels around Bolivia helping to set up testing labs, his experience with the equipment allows him to test a few samples to ensure everything is working properly.

After earning his degree at RIT, he went on to earn his Ph.D. in cellular and molecular biology at Harvard University in 2017 and is currently also a postdoctoral scholar in regeneration medicine at University of California, San Francisco.

Mostajo-Radji said he is proud to serve in this capacity and enjoys the work, but when looking back he is shocked at how quickly everything has escalated.

If you had asked me six months ago if I would have been doing this, I would have laughed, he said.

Continued here:
RIT Rallies: Biotechnology alumnus helping Bolivia respond to COVID-19 pandemic | College of Science - RIT University News Services

The report presents an in-depth assessment of the Biotechnology Reagents Market including enabling technologies, key trends, market drivers, challenges, standardization, regulatory landscape, deployment models, operator case studies, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents forecasts for Biotechnology Reagents investments from 2020 till 2026.

Global biotechnology reagents market is expected to rise from its initial estimated value of USD 65.82 billion in 2018 to an estimated value of USD 118.53 billion by 2026, registering a CAGR of 7.63% in the forecast period of 2019-2026.

Click the link to get a Sample Copy of the Report:

https://www.marketinsightsreports.com/reports/11191577929/global-biotechnology-reagents-market-professional-survey-report-2019/inquiry?source=coleofduty&Mode=48

The report presents the market competitive landscape and a corresponding detailed analysis of the major vendor/key players in the market. Top Companies in the Global Biotechnology Reagents Market: Agilent Technologies, Thermo Fisher Scientific, SGS, Shimadzu, Waters, Charles River Laboratories, Bioinformatics Solutions, Proteome Factory, Rapid Novor, Selvita

Biotechnology reagents are substances or compounds used to detect or synthesize another substance in order to give a reading test. These reagents are used in the field of research, genetics, molecular biology, diagnosis, immunology and bioscience. Biotechnology reagent consists of technologies such as cell culture, spectrometry, IVD, PCR, chromatography, expression and transfection, flow cytometer, and electrophoresis, and finds their application in various fields such as the immune phenotype, fluorescent microscopy, DNA analysis and cell cycle analysis.

This report segments on the basis of Types:

Life Science ReagentsAnalytical Reagents

Split On the basis of Applications:

Protein Synthesis and PurificationGene ExpressionDNA and RNA AnalysisDrug Testing

Inquire for Discount:

https://www.marketinsightsreports.com/reports/11191577929/global-biotechnology-reagents-market-professional-survey-report-2019/discount?source=coleofduty&Mode=48

Regional Analysis:

For comprehensive understanding of market dynamics, the global Biotechnology Reagents Market is analysed across key geographies namely: United States, China, Europe, Japan, South-east Asia, India and others. Each of these regions is analysed on basis of market findings across major countries in these regions for a macro-level understanding of the market.

Influence of the Biotechnology Reagents Market report:

-Comprehensive assessment of all opportunities and risk in the Biotechnology Reagents Market.

-Biotechnology Reagents Market recent innovations and major events.

-Detailed study of business strategies for growth of the Biotechnology Reagents Market-leading players.

-Conclusive study about the growth plot of Biotechnology Reagents Market for forthcoming years.

-In-depth understanding of Biotechnology Reagents Market-particular drivers, constraints and major micro markets.

-Favourable impression inside vital technological and market latest trends striking the Biotechnology Reagents Market.

The report has 150 tables and figures browse the report description and TOC:

https://www.marketinsightsreports.com/reports/11191577929/global-biotechnology-reagents-market-professional-survey-report-2019?source=coleofduty&Mode=48

What are the market factors that are explained in the report?

Key Strategic Developments: The study also includes the key strategic developments of the market, comprising R&D, new product launch, M&A, agreements, collaborations, partnerships, joint ventures, and regional growth of the leading competitors operating in the market on a global and regional scale.

Key Market Features: The report evaluated key market features, including revenue, price, capacity, capacity utilization rate, gross, production, production rate, consumption, import/export, supply/demand, cost, market share, CAGR, and gross margin. In addition, the study offers a comprehensive study of the key market dynamics and their latest trends, along with pertinent market segments and sub-segments.

Analytical Tools: The Global Biotechnology Reagents Market report includes the accurately studied and assessed data of the key industry players and their scope in the market by means of a number of analytical tools. The analytical tools such as Porters five forces analysis, feasibility study, and investment return analysis have been used to analysed the growth of the key players operating in the market.

Finally, Biotechnology Reagents Market report is the believable source for gaining the Market research that will exponentially accelerate your business. The report gives the principle locale, economic situations with the item value, benefit, limit, generation, supply, request and Market development rate and figure and so on. This report additionally Present new task SWOT examination, speculation attainability investigation, and venture return investigation.

Note: All the reports that we list have been tracking the impact of COVID-19. Both upstream and downstream of the entire supply chain has been accounted for while doing this. Also, where possible, we will provide an additional COVID-19 update supplement/report to the report in Q3, please check for with the sales team.

We Also Offer Customization on report based on specific client Requirement:

Free country Level analysis for any 5 countries of your choice.

Free Competitive analysis of any 5 key market players.

Free 40 analyst hours to cover any other data point.

About Us:

MarketInsightsReports provides syndicated market research on industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. MarketInsightsReports provides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact Us:

Irfan Tamboli (Head of Sales) Market Insights Reports

Phone: + 1704 266 3234 | +91-750-707-8687

[emailprotected] | [emailprotected]

Read more:
Biotechnology Reagents Market Analysis and Technology Advancement Outlook 2020 to 2025 - Cole of Duty

');},success: function(response) {$('.megamenuthird[data-menu=' + $data_megamenu + '-articles]').html(response);},error: function(xhr) { // if error occured$('.megamenuthird[data-menu=' + $data_megamenu + '-articles]').html("Error occured.please try again"); }});}}//Child Level Menu Hoverfunction get_childlevelmenu(currentid){//console.log('current id '+currentid);var $currentelement = $('#'+currentid);$('.menu-item-'+$('#'+currentid).closest('.themegamenu').attr('cid').split('-')[3]).removeClass('defaultajax-1');var $data_menu = $('#'+currentid).closest('li').data('menu');var ajaxreplaceContent = $('#'+currentid).closest('.themegamenu').data('megamenu')+'-articles';var submenu = $data_menu.split('-');var data_menu_class=submenu[0];//$('.megamenuthird').empty();$('.megamenuthird[data-menu=' + ajaxreplaceContent + ']').empty();$('li.level_2').removeClass('activeli');$currentelement.closest('li').siblings().removeClass('activeli');$currentelement.closest('li').addClass('activeli');var current_megamenu_second = $('.megamenusecond[data-menu='+$data_menu+']').length;$('.megamenuopen .megamenusecond').removeClass('megamenusecond-show');//$currentelement.closest('li').find('.megamenuopen .megamenusecond').removeClass('megamenusecond-show');$('.megamenusecond[data-menu=' + $data_menu + ']').addClass('megamenusecond-show');//if(current_megamenu_seconda').html();/********* End level3 checking menu ********/// checking 4th level menu /*** 4th level Objec code here **///getting parent data-menuvar levelfour_data_menu = $('.megamenusecond[data-menu='+$data_menu+']').find('li.level_3.activeli').data('menu');// End getting parent data-menuvar subofSubChildLevel_cat_id = $('.megamenusecond[data-menu='+levelfour_data_menu+']').find('li.level_4.activeli').data('cat');var subofSubChildLevel_data_menu = $('.megamenusecond[data-menu='+levelfour_data_menu+']').find('li.level_4.activeli').data('menu');var subofSubChildLevel_taxnomy_type= $('.megamenusecond[data-menu='+levelfour_data_menu+']').find('li.level_4.activeli').data('type');var subofSubChildLevel_title = $('.megamenusecond[data-menu='+levelfour_data_menu+']').find('li.level_4.activeli>a').html();if(subofSubChildLevel_title!=''){var ajx_title=subofSubChildLevel_title;}else{var ajx_title=subChildLevel_title;}/*** End 4th level Objec code here **/if(subofSubChildLevel_cat_id!=''){var data_obj ={'title':ajx_title,'subofSubChildLevel_cat_id':subofSubChildLevel_cat_id,'subofSubChildLevel_taxnomy_type':subofSubChildLevel_taxnomy_type,'subChildLevel_cat_id': subChildLevel_cat_id,'subChildLevel_taxnomy_type' :subChildLevel_taxnomy_type,'ChildLevel_data_type':ChildLevel_data_type,'ChildLevel_data_cat_id':ChildLevel_data_cat_id,'parent_data_cat_id':parent_data_cat_id,'parent_data_type':parent_data_type};}else{var data_obj ={'title':ajx_title,'subChildLevel_cat_id': subChildLevel_cat_id,'subChildLevel_taxnomy_type' :subChildLevel_taxnomy_type,'ChildLevel_data_type':ChildLevel_data_type,'ChildLevel_data_cat_id':ChildLevel_data_cat_id,'parent_data_cat_id':parent_data_cat_id,'parent_data_type':parent_data_type};}} if( ajaxRequestProject != null ) {ajaxRequestProject.abort();ajaxRequestProject = null;}ajaxRequestProject = $.ajax({type: 'POST',url: 'https://pharmaceutical-business-review.com/wp-admin/admin-ajax.php?action=mega_posts',data: data_obj, dataType: "html",beforeSend: function() {$('.megamenuthird[data-menu=' + ajaxreplaceContent+ ']').html('');},success: function(response) {$('.megamenuthird[data-menu=' + ajaxreplaceContent + ']').html(response);},error: function(xhr) { // if error occured$('.megamenuthird[data-menu=' + ajaxreplaceContent + ']').html("Error occured.please try again");}});}//Subchild Level Menu Hover//Child Level Menu Hoverfunction get_subchildlevelmenu(currentid){var $currentelement = $('#'+currentid);$('.menu-item-'+$('#'+currentid).closest('.themegamenu').attr('cid').split('-')[3]).removeClass('defaultajax-1');var $data_menu = $currentelement.closest('li').attr('data-menu'); var submenu = $data_menu.split('-'); var data_menu_class=submenu[0];var ajaxreplaceContent = $('#'+currentid).closest('.themegamenu').data('megamenu')+'-articles';$('.megamenuthird[data-menu=' + ajaxreplaceContent + ']').empty();$('.megamenuthird').removeClass('megamenuthird-show');$('.megamenuthird[data-menu=' + $data_menu + ']').addClass('megamenuthird-show');$('li.level_3').removeClass('activeli');$currentelement.closest('li').addClass('activeli');var subChildLevel_title = $currentelement.html();//last child level$currentelement.closest('li').parent().closest('li').find('.megamenusecond-new[data-menu=' + $data_menu + ']').find('li.level_4').removeClass('activeli');var $data_menu = $('#'+currentid).closest('li').data('menu');$('.megamenuopen .megamenusecond-new').removeClass('megamenusecond-show');$currentelement.closest('li').parent().closest('li').find('.megamenusecond-new[data-menu=' + $data_menu + ']').addClass('megamenusecond-show');$currentelement.closest('li').parent().closest('li').find('.megamenusecond-new[data-menu=' + $data_menu + ']').find('li.level_4:first-child').addClass('activeli');//console.log('subchild-'+title);var subChildLevel_cat_id=$currentelement.closest('li').data("cat");var subChildLevel_taxnomy_type = $currentelement.closest('li').data("type");var ChildLevel_data_type= $(".mega-options > li.project_m.activeli").data("type");var ChildLevel_data_cat_id= $(".mega-options > li.project_m.activeli").data("cat_id");var parent_data_cat_id= $currentelement.closest('.themegamenu').data("main_cat_id");var parent_data_type= $currentelement.closest('.themegamenu').data("main_type");// checking 4th level menu /*** 4th level Objec code here **/// End getting parent data-menuif($('.megamenusecond.megamenusecond-new').length > 0){var subofSubChildLevel_cat_id = $('.megamenusecond[data-menu='+$data_menu+']').find('li.level_4.activeli').data('cat');var subofSubChildLevel_data_menu = $('.megamenusecond[data-menu='+$data_menu+']').find('li.level_4.activeli').data('menu');var subofSubChildLevel_taxnomy_type= $('.megamenusecond[data-menu='+$data_menu+']').find('li.level_4.activeli').data('type');var subofSubChildLevel_title = $('.megamenusecond[data-menu='+$data_menu+']').find('li.level_4.activeli>a').html();if(subofSubChildLevel_title!==''){var ajx_title=subofSubChildLevel_title;}else{var ajx_title=subChildLevel_title;}if(subofSubChildLevel_cat_id!=''){var data_obj= {'title':ajx_title,'subofSubChildLevel_cat_id':subofSubChildLevel_cat_id,'subofSubChildLevel_taxnomy_type':subofSubChildLevel_taxnomy_type,'subChildLevel_cat_id': subChildLevel_cat_id,'subChildLevel_taxnomy_type' :subChildLevel_taxnomy_type,'ChildLevel_data_type':ChildLevel_data_type,'ChildLevel_data_cat_id':ChildLevel_data_cat_id,'parent_data_cat_id':parent_data_cat_id,'parent_data_type':parent_data_type};}else{var data_obj= {'title':ajx_title,'subChildLevel_cat_id': subChildLevel_cat_id,'subChildLevel_taxnomy_type' :subChildLevel_taxnomy_type,'ChildLevel_data_type':ChildLevel_data_type,'ChildLevel_data_cat_id':ChildLevel_data_cat_id,'parent_data_cat_id':parent_data_cat_id,'parent_data_type':parent_data_type};}}else{var data_obj= {'title':subChildLevel_title,'subChildLevel_cat_id': subChildLevel_cat_id,'subChildLevel_taxnomy_type' :subChildLevel_taxnomy_type,'ChildLevel_data_type':ChildLevel_data_type,'ChildLevel_data_cat_id':ChildLevel_data_cat_id,'parent_data_cat_id':parent_data_cat_id,'parent_data_type':parent_data_type};} if( ajaxRequestProject != null ) {ajaxRequestProject.abort();ajaxRequestProject = null;}ajaxRequestProject = $.ajax({ type: 'POST', url: 'https://pharmaceutical-business-review.com/wp-admin/admin-ajax.php?action=mega_posts', dataType: "html", data: data_obj, beforeSend: function() {$('.megamenuthird[data-menu=' + ajaxreplaceContent + ']').html('');},success: function(response) {$('.megamenuthird[data-menu=' + ajaxreplaceContent + ']').html(response);},error: function(xhr) { // if error occured$('.megamenuthird[data-menu=' + ajaxreplaceContent + ']').html("Error occured.please try again"); }});}//last child levelfunction get_lastchildlevelmenu(currentid){var $currentelement = $('#'+currentid);$('.menu-item-'+$('#'+currentid).closest('.themegamenu').attr('cid').split('-')[3]).removeClass('defaultajax-1');var $data_menu = $currentelement.closest('li').attr('data-menu'); var submenu = $data_menu.split('-'); var data_menu_class=submenu[0];var $ajax_data_menu = $currentelement.closest('li').attr('data-ajax'); var ajax_submenu = $ajax_data_menu.split('-'); var ajax_data_menu_class=ajax_submenu[0]+'-'+ajax_submenu[1];var ajaxreplaceContent = $('#'+currentid).closest('.themegamenu').data('megamenu')+'-articles';$('.megamenuthird[data-menu=' + ajaxreplaceContent + ']').empty();$('.megamenuthird').removeClass('megamenuthird-show');$('.megamenuthird[data-menu=' + $data_menu + ']').addClass('megamenuthird-show');$('li.level_4').removeClass('activeli');$currentelement.closest('li').addClass('activeli');var title = $currentelement.html();var subofSubChildLevel_cat_id=$currentelement.closest('li').data("cat");var subofSubChildLevel_taxnomy_type = $currentelement.closest('li').data("type");var subofSubChildLevel_title = $currentelement.closest('li').find('li.level_4.activeli>a').html();var subChildLevel_cat_id=$('.megamenusecond[data-menu='+ajax_data_menu_class+']').find('li.level_3.activeli').data('cat');var subChildLevel_data_menu=$('.megamenusecond[data-menu='+ajax_data_menu_class+']').find('li.level_3.activeli').data('menu');var subChildLevel_taxnomy_type = $('.megamenusecond[data-menu='+ajax_data_menu_class+']').find('li.level_3.activeli').data('type');var ChildLevel_data_type= $(".mega-options > li.project_m.activeli").data("type");var ChildLevel_data_cat_id= $(".mega-options > li.project_m.activeli").data("cat_id");var parent_data_cat_id= $currentelement.closest('.themegamenu').data("main_cat_id");var parent_data_type= $currentelement.closest('.themegamenu').data("main_type");var data_obj= {'title':title,'subofSubChildLevel_cat_id':subofSubChildLevel_cat_id,'subofSubChildLevel_taxnomy_type':subofSubChildLevel_taxnomy_type,'subChildLevel_cat_id': subChildLevel_cat_id,'subChildLevel_taxnomy_type' :subChildLevel_taxnomy_type,'ChildLevel_data_type':ChildLevel_data_type,'ChildLevel_data_cat_id':ChildLevel_data_cat_id,'parent_data_cat_id':parent_data_cat_id,'parent_data_type':parent_data_type};if( ajaxRequestProject != null ) {ajaxRequestProject.abort();ajaxRequestProject = null;}ajaxRequestProject = $.ajax({ type: 'POST', url: 'https://pharmaceutical-business-review.com/wp-admin/admin-ajax.php?action=mega_posts', dataType: "html", data:data_obj, beforeSend: function() {$('.megamenuthird[data-menu=' + ajaxreplaceContent + ']').html('');},success: function(response) {$('.megamenuthird[data-menu=' + ajaxreplaceContent + ']').html(response);},error: function(xhr) { // if error occured$('.megamenuthird[data-menu=' + ajaxreplaceContent + ']').html("Error occured.please try again"); }});} $(document).ready(function(){//$('body').addClass('loaded');/********* End Third Level on over show/hide ****/$('.news-box-big').hover(function() {$(this).closest('.news').children('.big_title').toggleClass("bordertop");});$('.news-box-medium').hover(function() {$(this).closest('.medium_title').children('.tbt').toggleClass("bordertop");}); /********* Newsletter onclick events start here *******/ $(".header-cta a").click(function(e){ var $elem = $('.newsletter-box').position(); $('html,body').animate({ scrollTop: $(".newsletter-box").offset().top - 80}, 'fast'); }); /***** Newsletter onclick events End here *******/ /* Close guided tour */ $(".close-guided-tour").click(function(){$(".home_timeline").hide(); }); /* Close guided tour */ $(".close-guided-tour2").click(function(){ $(".timeline-tour2").hide(); }); /* $( ".fa-search" ).click(function() { $( 'body' ).toggleClass('search-open'); //$('.search-form').toggle(); }); $('.search-toggle').click(function () {$('.search-form').toggleClass('expanded');}); */ // Search toggle$('.navbar .search-toggle, .mobilesearch').click(function(e){e.preventDefault();$(this).parent().toggleClass('active').find('input[type="search"]').focus();});$('.search-submit').click(function(e){if( $(this).parent().find('.search-field').val() == '' ) {e.preventDefault();$(this).parent().parent().removeClass('active');}}); }); /* Reached newsletter */ $(function(){ $(document).scroll(function(){ if($(this).scrollTop() >= $('.email-capture').offset().top - 50) { $('body').addClass("email-capture-reached"); } else{ $('body').removeClass("email-capture-reached"); } if($(this).scrollTop() >= $('.timeline').offset().top - 50) { $('body').addClass("timeline-tour-open"); } else{ $('body').removeClass("timeline-tour-open"); } }); }); /****** Article page Share n/w ********/ $('.social-toggle').on('click', function() { $(this).next().toggleClass('open-menu'); }); /*** End Article page Share n/w ********/ /* Close guided tour */ $(".close-guided-tour2").click(function(){ $("body").addClass("timeline-closed"); }); /* End Timeline guided tour Track the news */ /* Reached related headline */ $(function(){ $(document).ready(function(){ $('body').addClass("headline-reached"); }); }); /* Reached start */ /*$(function(){ $(document).scroll(function(){ if($(this).scrollTop() >= $('#start').offset().top - 50) { $('body').addClass("start-reached"); } else{ $('body').removeClass("start-reached"); } }); });*/ /* Reached share-content */ $(function(){ $(document).scroll(function(){ if($(this).scrollTop() >= $('.share-content').offset().top - 50) { $('body').addClass("share-content-reached"); } else{ $('body').removeClass("share-content-reached"); } }); }); /* share copy-link section */ function myFunction() { var copyText = document.getElementById("copylink"); copyText.select(); document.execCommand("Copy"); } /* Reached first sidebar mpu */ $(function(){ $(document).scroll(function(){ if($(this).scrollTop() >= $('.mpu1').offset().top - 50) { $('body').addClass("reached-mpu1"); } else{ $('body').removeClass("reached-mpu1"); } }); }); /* Sticky sidebar banner */ /* $(function(){ $(document).scroll(function(){ if ($(window).width() > 1400) { if($(this).scrollTop() >= $('#sticky-mpu').offset().top - 250 ) { $('.sidebar').addClass("banner-fixed"); } else{ $('.sidebar').removeClass("banner-fixed"); } } }); });*/ // Select all links with hashes $('a[href*="#"]') // Remove links that don't actually link to anything .not('[href="#"]') .not('[href="#0"]') .click(function(event) { // On-page links if ( location.pathname.replace(/^//, '') == this.pathname.replace(/^//, '') && location.hostname == this.hostname ) { // Figure out element to scroll to var target = $(this.hash); target = target.length ? target : $('[name=' + this.hash.slice(1) + ']'); // Does a scroll target exist? if (target.length) { // Only prevent default if animation is actually gonna happen event.preventDefault(); $('html, body').animate({ scrollTop: target.offset().top }, 1000, function() { // Callback after animation // Must change focus! var $target = $(target); $target.focus(); if ($target.is(":focus")) { // Checking if the target was focused return false; } else { $target.attr('tabindex','-1'); // Adding tabindex for elements not focusable $target.focus(); // Set focus again }; }); } } }); /******** onclick share button in catgeory page ******/ $(".share-button").click(function(){ if($(this).parent('.open-share').length == 0){ $('.share').removeClass('open-share'); $(this).parent('.share').addClass("open-share"); }else{ $('.share').removeClass('open-share'); } }); /************* Mobile menu js *******/ function openNav() { document.getElementById("mobilemenu").style.width = "100%"; document.getElementById("mobilemenu").style.left = "0px"; } function closeNav() { document.getElementById("mobilemenu").style.width = "0"; } $( ".mobilemenuicon" ).click(function() { setTimeout(function(){ $( '.mobile-menu-cta' ).addClass("mobilectashow"); }, 500); }); $( ".closebtn" ).click(function() { $( '.mobile-menu-cta' ).removeClass("mobilectashow") }); /********** End mobile menu js *******/ /********* contractors Single page close Header**/ $(".close_section").click(function(){ $('.headersf').hide(1000); $('.headersf').addClass('section_closed'); $('.header-singleproduct').addClass('margin_top_added'); $('.small_header_sf').addClass('small_header_sf_display'); }); /******* End contractors Single page close Header**/ /*** My accout drop down menu */ $('.ctanav .dropdown-menu a').on('click', function() { window.location.href = $(this).attr('href'); }); /*** cookie-popup **/ $("#cookiepopup-continue").click(function(){ $.cookie("cookie_compelo", 'https://pharmaceutical-business-review.com'); $('.home_timeline').hide(); }); $(window).on("load",function(){ var data = $.cookie("cookie_compelo"); if(data){ $('.home_timeline').hide(); }else{ $('.home_timeline').show(); } }); $(".home_timeline .close").click(function(){ $.cookie("cookie_compelo", 'https://pharmaceutical-business-review.com'); $('.home_timeline').hide(); }); $(window).on("load",function(){ var data = $.cookie("cookie_compelo"); if(data){ $('.home_timeline').hide(); }else{ $('.home_timeline').show(); } }); /*** End cookie popup **/ /**** New add js code ***/ if ($(window).width() > 960) { // Initialization $(function(){ $('[data-scroll-speed]').moveIt(); }); } /* Sticky sidebar banner EVENT PAGE */ $(function(){ $(document).scroll(function(){ var scroll = $(window).scrollTop(); if (scroll >= 655) { $('.sticky-mpu-event').addClass("banner-fixed"); } else{ $('.sticky-mpu-event').removeClass("banner-fixed"); } }); }); //advertising page jQuery.fn.moveIt = function(){ var $window = jQuery(window); var instances = []; jQuery(this).each(function(){ instances.push(new moveItItem($(this))); }); window.addEventListener('scroll', function(){ var scrollTop = $window.scrollTop(); instances.forEach(function(inst){ inst.update(scrollTop); }); }, {passive: true}); } var moveItItem = function(el){ this.el = jQuery(el); this.speed = parseInt(this.el.attr('data-scroll-speed')); }; moveItItem.prototype.update = function(scrollTop){ this.el.css('transform', 'translateY(' + -(scrollTop / this.speed) + 'px)');};// InitializationjQuery(function(){jQuery('[data-scroll-speed]').moveIt();}); /**** end new add js code **/

Visit link:
AgeX Therapeutics, ImStem Biotechnology sign non-binding letter of intent regarding investigational MSC candidate IMS001 for Covid-19 - Pharmaceutical...

Global Media, Sera and Reagents in Biotechnology Market: Trends Estimates High Demand by 2027

The Media, Sera and Reagents in Biotechnology Market 2020 report includes the market strategy, market orientation, expert opinion and knowledgeable information. The Media, Sera and Reagents in Biotechnology Industry Report is an in-depth study analyzing the current state of the Media, Sera and Reagents in Biotechnology Market. It provides a brief overview of the market focusing on definitions, classifications, product specifications, manufacturing processes, cost structures, market segmentation, end-use applications and industry chain analysis. The study on Media, Sera and Reagents in Biotechnology Market provides analysis of market covering the industry trends, recent developments in the market and competitive landscape.

It takes into account the CAGR, value, volume, revenue, production, consumption, sales, manufacturing cost, prices, and other key factors related to the global Media, Sera and Reagents in Biotechnology market. All findings and data on the global Media, Sera and Reagents in Biotechnology market provided in the report are calculated, gathered, and verified using advanced and reliable primary and secondary research sources. The regional analysis offered in the report will help you to identify key opportunities of the global Media, Sera and Reagents in Biotechnology market available in different regions and countries.

The final report will add the analysis of the Impact of Covid-19 in this report Media, Sera and Reagents in Biotechnology industry.

Some of The Companies Competing in The Media, Sera and Reagents in Biotechnology Market are: Athena Environmental Science, Inc., Becton, Dickinson, CellGenix, GE Healthcare, Lonza, Thermo Fisher Scientific, Inc., and

Get a Sample Copy of the [emailprotected] https://www.reportsandmarkets.com/sample-request/covid-19-impact-on-global-media-sera-and-reagents-in-biotechnology-market-size-status-and-forecast-2020-2026?utm_source=coleofduty&utm_medium=24

The report scrutinizes different business approaches and frameworks that pave the way for success in businesses. The report used Porters five techniques for analyzing the Media, Sera and Reagents in Biotechnology Market; it also offers the examination of the global market. To make the report more potent and easy to understand, it consists of info graphics and diagrams. Furthermore, it has different policies and improvement plans which are presented in summary. It analyzes the technical barriers, other issues, and cost-effectiveness affecting the market.

Global Media, Sera and Reagents in Biotechnology Market Research Report 2020 carries in-depth case studies on the various countries which are involved in the Media, Sera and Reagents in Biotechnology market. The report is segmented according to usage wherever applicable and the report offers all this information for all major countries and associations. It offers an analysis of the technical barriers, other issues, and cost-effectiveness affecting the market. Important contents analyzed and discussed in the report include market size, operation situation, and current & future development trends of the market, market segments, business development, and consumption tendencies. Moreover, the report includes the list of major companies/competitors and their competition data that helps the user to determine their current position in the market and take corrective measures to maintain or increase their share holds.

What questions does the Media, Sera and Reagents in Biotechnology market report answer pertaining to the regional reach of the industry?

The report claims to split the regional scope of the Media, Sera and Reagents in Biotechnology market into North America, Europe, Asia-Pacific, South America & Middle East and Africa. Which among these regions has been touted to amass the largest market share over the anticipated duration

How do the sales figures look at present how does the sales scenario look for the future?

Considering the present scenario, how much revenue will each region attain by the end of the forecast period?

How much is the market share that each of these regions has accumulated presently

How much is the growth rate that each topography will depict over the predicted timeline

A short overview of the Media, Sera and Reagents in Biotechnology market scope:

Global market remuneration

Overall projected growth rate

Industry trends

Competitive scope

Product range

Application landscape

Supplier analysis

Marketing channel trends Now and later

Sales channel evaluation

Market Competition Trend

Market Concentration Rate

Reasons to Read this Report

This report provides pin-point analysis for changing competitive dynamics

It provides a forward looking perspective on different factors driving or restraining market growth

It provides a six-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

TABLE OF CONTENT:

Chapter 1:Media, Sera and Reagents in Biotechnology Market Overview

Chapter 2: Global Economic Impact on Industry

Chapter 3:Media, Sera and Reagents in Biotechnology Market Competition by Manufacturers

Chapter 4: Global Production, Revenue (Value) by Region

Chapter 5: Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6: Global Production, Revenue (Value), Price Trend by Type

Chapter 7: Global Market Analysis by Application

Chapter 8: Manufacturing Cost Analysis

Chapter 9: Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10: Marketing Strategy Analysis, Distributors/Traders

Chapter 11: Media, Sera and Reagents in Biotechnology Market Effect Factors Analysis

Chapter 12: GlobalMedia, Sera and Reagents in Biotechnology Market Forecast to 2027

Get Complete Report @ https://www.reportsandmarkets.com/sample-request/covid-19-impact-on-global-media-sera-and-reagents-in-biotechnology-market-size-status-and-forecast-2020-2026?utm_source=coleofduty&utm_medium=24

About Us:

Reports And Markets is part of the Algoro Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Are you mastering your market? Do you know what the market potential is for your product, who the market players are and what the growth forecast is? We offer standard global, regional or country specific market research studies for almost every market you can imagine.

Contact Us:

Sanjay Jain

Manager Partner Relations & International Marketing

http://www.reportsandmarkets.com

Ph: +1-352-353-0818 (US)

Read more here:
Research on Media, Sera and Reagents in Biotechnology Market (impact of COVID-19) with Top Players: Athena Environmental Science, Inc., Becton,...

Thanks to its newly announced COVID-19 antibody therapy candidates, Vir Biotechnology's (NASDAQ:VIR) stock is still up more than 10% from the beginning of May and more than 180% from the start of the year.On top of its recent gains, there's reason to believe that Vir is positioned perfectly for continued growth.

While the company has a long way to go before it reaches profitability, between its low-risk pipeline programs for COVID-19 and a demonstrated competency for preclinical drug development for infectious disease, Vir's future seems bright.

Image source: Getty Images.

Vir's preclinical COVID-19 projects include two antibody therapies that it claims could temporary prevention and the treatment of coronavirus infections. VIR-7832 is both a prophylactic and a therapeutic, whereas VIR-7831 is only a therapeutic.

Because they are antibody therapies, Vir's candidates would be more effective at helping sick patients get better by reducing their viral load than it would be at preventing infections like a traditional vaccine might. In a nutshell, both of Vir's antibody programs could help patients to fight COVID-19 immediately by neutralizing viral particles in their bloodstream after they get a dose of the therapy. Then, once the patient's symptoms subside, the antibodies would remain in their system for several days or weeks, protecting them from re-infection. This process is key to both of Vir's COVID-19 antibody programs, but there's a bit more to the story.

Vir suspects that VIR-7832 may also function as a T-cell vaccine, training the immune system to react to future infections. This would mean that patients could be administered the antibody even if they don't expect to get sick. If Vir's hunch is correct, VIR-7832 would provide longer-lasting immunity than VIR-7831, and it might be a contender for mass production as a prophylactic.

The company's approach is uncontroversial from a scientific perspective, given that neutralizing antibodies from COVID-19 survivors have already been shown to combat the disease in vitro by numerous independent research teams and similar therapies were successfully used to treat human patients with SARS. Similarly, Vir's approach is front-run by ongoing clinical trials testing the efficacy of antibodies from recovered COVID-19 patients on improving disease outcomes in people who are currently ill.

The average vaccine in development is estimated to have only a 6% chance of proceeding all the way to approval and the market, but Vir's antibody products may fare better because they are adapted from natural antibodies known to be effective and safe. There's no guarantee of Vir's efforts ending in blockbuster revenue, but in the highly risky world of biotech, the prospects of these two COVID-19 projects are extremely favorable even from a conservative perspective.

However, given that the antibodies would be copies of naturally ocurring antibodies, it's uncertain whether intellectual property protection would be sufficient to prevent a competitor from creating very similar products. For most biotech companies, this would be a dealbreaker, as it would effectively prevent the ability to recoup development costs with a period of exclusive production rights. But not for Vir. By bucking the traditional wisdom regarding exclusivity and drug development, Vir has a real chance of entering the market sooner than competitors at a time when demand for its product would be enormously high.

That isn't to say that Vir is an unambitious company because it is moving forward with safer programs. In contrast to its two antibody therapy programs, Vir's VIR-2703 program is riskier because it uses a scientific approach which hasn't been tested in humans for the purpose of infectious disease. Rather than acting to neutralize viral particles directly like an antibody might, VIR-2703 relies on small chunks of genetic information called silencing RNAs (siRNAs) which disrupt regions of the viral genome.

Counting on this program to succeed would be a mistake. Most large pharmaceutical companies gave up trying to develop siRNA therapies in the mid-2010s after nearly a decade of failures, and the only siRNA therapy approved by the FDA isn't for an infectious disease.

On the other hand, early favorable clinical results from VIR-2703 should not be interpreted as a reason to buy the company's stock. Stumbles stemming from a lack of a proof of concept in human patients further down the pipeline could easily erase any gains. Either way, Vir's drug development pipeline looks more like a risk-balanced portfolio than a selection of technological and scientific gambles like so many other biotechs.

If Vir brings one of its COVID-19 programs to market, it'll be one more addition to the company's impressive roster of therapies and prophylactics for viral diseases. Aside from its three unique COVID-19 programs, Vir's pipeline includes a handful of other projects intended to treat or prevent illnesses caused by hepatitis B, influenza, tuberculosis, and even HIV. Importantly, all but two of these pipeline projects are in the preclinical phase, so the company's clinical acumen is far from proven.

In terms of advanced programs, the closest Vir has to offer is its VIR-2218 therapy for hepatitis B, which it suspects may be curative for most patients. If Vir brings a curative therapy to market, the company may have trouble maintaining its revenue over the long term because a cure shrinks the pool of eligible patients. As the hepatitis B therapeutics market is only worth around $2.6 billion, it's possible that Vir's hepatitis B therapy would meet the same fate as the low-earning hepatitis C therapy produced by Gilead Sciences (NASDAQ:GILD)But, with 257 million people worldwide living with hepatitis B compared to only 71 million living with hepatitis C, it's less likely that Vir will experience the same difficulties. Importantly, Vir isn't letting Gilead's experience stop them from moving forward with a curative therapy candidate. Even if the long-term profitability of VIR-2218 is in jeopardy of being a victim of its own success, Vir is willing to take a chance rather than stick to a safer opportunity.

In summary, Vir's COVID-19 pipeline has two antibody programs that have a better than average chance of passing through clinical trials.Elsewhere, the company's technology platform appears formidable, but its clinical pipeline is still in its infancy, despite a bevy of compelling seedlings.

Given the level of public need for COVID-19 treatments and vaccines, it's likely that if Vir's COVID-19 programs look promising once they hit the clinic in the summer, they'll be expedited through clinical trials. This means that the company's minimal past experience in clinical operations and clinical development will be of little use, so it's likely to need to lean heavily on larger collaborators like Biogen, GlaxoSmithKline, and Alnylam Pharmaceuticals.

It's easy to envision a future where Vir gets acquired by one of these collaborators if its trials have positive outcomes. In the meantime, progress by Vir's major competitors like Novavax and behemoth vaccine producers like Merck is unlikely to diminish the company's upward trajectory, as competing products would be targeted at preventing COVID-19 rather than both treating and preventing it.

Image Source: YCharts

As the market grows to recognize Vir as a rising contender in the COVID-19 therapeutic market, public interest in the company will explode, to the benefit of its shareholders. I'd recommend buying Vir shares now, to maximize the benefit of successive boosts to the company's stock price as its COVID-19 candidates pass through each phase of clinical trials. Holding onto Vir for a few years will maximize the gains, but don't discount the probability of near-term gains either.

See the original post:
Vir Biotechnology Is Bucking The Biotech COVID-19 Trends, And Stands To Win - Motley Fool

Global Biotechnology Market Report is a professional and in-depth research report on the worlds major regional market. The Biotechnology industry2020 by Industry Demand, Business Strategy & Emerging Trends by Leading Players. The Global pandemic of COVID19/CORONA Virus calls for redefining of business strategies. This Biotechnology Market report includes the impact analysis necessary for the same.

Download the Sample ToC to understand the CORONA Virus/COVID19 impact and be smart in redefining business strategies. https://inforgrowth.com/CovidImpact-Request/6321901/biotechnology-market

Top Players Listed in the Biotechnology Market Report areJohnson & Johnson, Roche, Pfizer, Merck, Sanofi, AstraZeneca, Gilead, CELGENE CORPORATION, Biogen, Amgen, Abbott, Novo Nordisk, Novartis, Lonza, .

Biotechnologymarket report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, the impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market Segmentations: Global Biotechnology market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer.

Based on type, report split into DNA Sequencing, Nanobiotechnology, Tissue engineering and Regeneration, Fermentation, Cell Based Assay, PCR Technology, Chromatography Market, Others.

Based on the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including Health, Food & Agriculture, Natural Resources & Environment, Industrial Processing, Bioinformatics.

Get Exclusive Sample of Report on Biotechnology market is available at https://inforgrowth.com/sample-request/6321901/biotechnology-market

The report introduces Biotechnology basic information including definition, classification, application, industry chain structure, industry overview, policy analysis, and news analysis. Insightful predictions for the Biotechnology Market for the coming few years have also been included in the report.

In the end, Biotechnologyreport provides details of competitive developments such as expansions, agreements, new product launches, and acquisitions in the market for forecasting, regional demand, and supply factor, investment, market dynamics including technical scenario, consumer behavior, and end-use industry trends and dynamics, capacity, spending were taken into consideration.

Important Key questions answered in Biotechnologymarket report:

Get Special Discount Up To 50%, https://inforgrowth.com/discount/6321901/biotechnology-market

FOR ALL YOUR RESEARCH NEEDS, REACH OUT TO US AT:Address: 6400 Village Pkwy suite # 104, Dublin, CA 94568, USAContact Name: Rohan S.Email:[emailprotected]Phone: +1-909-329-2808UK: +44 (203) 743 1898Website: http://www.inforgrowth.com

See the article here:
COVID-19 Update: Global Biotechnology Market is Expected to Grow at a Healthy CAGR with Top players: Johnson & Johnson, Roche, Pfizer, Merck,...